Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

被引:0
作者
Antonio Braga [1 ,2 ]
Paulo Mora [1 ,3 ]
Andréia Cristina de Melo [3 ]
Angélica Nogueira-Rodrigues [4 ]
Joffre Amim-Junior [2 ]
Jorge Rezende-Filho [2 ]
Michael J Seckl [5 ]
机构
[1] Postgraduate Program of Medical Sciences, Fluminense Federal University
[2] Department of Gynecology and Obstetrics, Faculty of Medicine, Rio de Janeiro Federal University, Postgraduate Program of Perinatal Health, Maternity School
[3] Brazilian National Cancer, Hospital do Cancer 2  4. Department of Internal Medicine, Faculty of Medicine, Minas Gerais Federal University  5. De
关键词
Gestational trophoblastic neoplasia; Chemotherapy; Chorionic gonadotropin; Invasive mole; Choriocarcinoma; Placental site trophoblastic tumor; Epithelioid trophoblastic tumor;
D O I
暂无
中图分类号
R737.33 [子宫肿瘤];
学科分类号
100214 ;
摘要
Gestational trophoblastic neoplasia(GTN) is a rare tumor that originates from pregnancy that includes invasive mole, choriocarcinoma(CCA), placental site trophoblastic tumor and epithelioid trophoblastic tumor(PSTT/ETT). GTN presents different degrees of proliferation, invasion and dissemination, but, if treated in reference centers, has high cure rates, even in multi-metastatic cases.The diagnosis of GTN following a hydatidiform molar pregnancy is made according to the International Federation of Gynecology and Obstetrics(FIGO)2000 criteria: four or more plateaued human chorionic gonadotropin(hCG)concentrations over three weeks; rise in hCG for three consecutive weekly measurements over at least a period of 2 weeks or more; and an elevated but falling hCG concentrations six or more months after molar evacuation. However,the latter reason for treatment is no longer used by many centers. In addition,GTN is diagnosed with a pathological diagnosis of CCA or PSTT/ETT. For staging after a molar pregnancy, FIGO recommends pelvic-transvaginal Doppler ultrasound and chest X-ray. In cases of pulmonary metastases with more than 1cm, the screening should be complemented with chest computed tomography and brain magnetic resonance image. Single agent chemotherapy, usually Methotrexate(MTX) or Actinomycin-D(Act-D), can cure about 70% of patients with FIGO/World Health Organization(WHO) prognosis risk score ≤ 6(low risk), reserving multiple agent chemotherapy, such as EMA/CO(Etoposide,MTX, Act-D, Cyclophosphamide and Oncovin) for cases with FIGO/WHO prognosis risk score ≥ 7(high risk) that is often metastatic. Best overall cure rates for low and high risk disease is close to 100% and > 95%, respectively. The management of PSTT/ETT differs and cure rates tend to be a bit lower. The early diagnosis of this disease and the appropriate treatment avoid maternal death,allow the healing and maintenance of the reproductive potential of these women.
引用
收藏
页码:28 / 37
页数:10
相关论文
共 21 条
[1]  
Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients[J] . Fang Jiang,Xi-run Wan,Tao Xu,Feng-zhi Feng,Tong Ren,Jun-jun Yang,Jun Zhao,Tao Yang,Yang Xiang.Gynecologic Oncology . 2018 (3)
[2]  
Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?[J] . Antonio Braga,Andressa Biscaro,Jessye Melgarejo do Amaral Giordani,Maurício Viggiano,Kevin M. Elias,Ross S. Berkowitz,Michael J. Seckl.European Journal of Obstetrics and Gynecology . 2018
[3]  
Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia[J] . Ehsan Ghorani,Baljeet Kaur,Rosemary A Fisher,Dee Short,Ulrika Joneborg,Joseph W Carlson,Ayse Akarca,Teresa Marafioti,Sergio A Quezada,Naveed Sarwar,Michael J Seckl.The Lancet . 2017 (1011)
[4]   Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors? [J].
Sobral Dantas, Patricia Rangel ;
Maesta, Izildinha ;
Rezende Filho, Jorge ;
Amin Junior, Joffre ;
Elias, Kevin M. ;
Howoritz, Neil ;
Braga, Antonio ;
Berkowitz, Ross S. .
GYNECOLOGIC ONCOLOGY, 2017, 147 (02) :364-370
[5]  
Update on the diagnosis and management of gestational trophoblastic disease[J] . Hextan Y.S. Ngan,Michael J. Seckl,Ross S. Berkowitz,Yang Xiang,Fran?ois Golfier,P.K. Sekharan,John R. Lurain.International Journal of Gynecology and Obstetric . 2015
[6]  
Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5–6[J] . A Sita‐Lumsden,H Medani,R Fisher,R Harvey,D Short,N Sebire,P Savage,A Lim,MJ Seckl,R Agarwal.BJOG . 2013 (8)
[7]   Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia [J].
Mapelli, P. ;
Mangili, G. ;
Picchio, M. ;
Gentile, C. ;
Rabaiotti, E. ;
Giorgione, V. ;
Spinapolice, E. G. ;
Gianolli, L. ;
Messa, C. ;
Candiani, M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :505-513
[8]   Current advances in the management of gestational trophoblastic disease [J].
Berkowitz, Ross S. ;
Goldstein, Donald Peter .
GYNECOLOGIC ONCOLOGY, 2013, 128 (01) :3-5
[9]  
Trophoblastic disease[J] . Hextan Y.S. Ngan,Ernest I. Kohorn,Laurence A. Cole,Robert J. Kurman,Seung J. Kim,John R. Lurain,Michael J. Seckl,Shigeru Sasaki,John T. Soper.International Journal of Gynecology and Obstetrics . 2012
[10]  
Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study[J] . Roshan Agarwal,Suliana Teoh,Delia Short,Richard Harvey,Philip M Savage,Michael J Seckl.The Lancet . 2012 (9811)